Healthcare Research Consultants

Tulsa, Oklahoma 74135-2920

0 studies enrolling now · 27 studies all time

What they study most

Arthritis, Rheumatoid, Autoimmune Diseases, Chronic Bronchitis, Chronic Hepatitis C, Chronic Obstructive Pulmonary Disease, Emphysema, Hepatitis C, Hepatitis C Infection, Hepatitis C Virus, Hepatitis C Virus (HCV), Immunologic Diseases, Juvenile Idiopathic Arthritis

Studies at this site

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis — Completed
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections — Stopped early
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis — Completed
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen — Completed
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab — Stopped early
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) — Stopped early
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir — Completed
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX — Completed
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis — Completed
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis — Completed
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications — Completed
Methotrexate-Inadequate Response Study — Completed
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. — Completed
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) — Completed
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care — Completed
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin — Completed
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
A Study of Abatacept in Patients With Active Ulcerative Colitis — Completed
Phase IIIB Subcutaneous Abatacept Monotherapy Study — Completed
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD — Completed
Study of LJP 394 in Lupus Patients With History of Renal Disease — Stopped early
CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission — Completed
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease — Completed